相关实验视频

Updated: Sep 14, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

尼沃卢马布与R-CHOP结合用于治疗-先天扩散大B细胞淋巴瘤:安全性和有效性的评估

Oluwatobi Odetola¹, Shuo Ma², Jane N Winter³

¹Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States.

|July 24, 2025

概括

前线尼沃卢马布加R-CHOP在扩散型大B细胞淋巴瘤患者中显示出有前途的生存率. 组合疗法显示出良好的安全性,并没有恶化患者的生活质量.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学恶性瘤是什么

背景情况:

大约20%的扩散型大B细胞淋巴瘤 (DLBCL) 病例涉及PD-L1/PD-L2位置异常.
目前正在研究PD-1检查点抑制剂作为前线治疗,以改善高风险DLBCL患者的治疗结果.

研究的目的:

评估nivolumab (一种PD-1抑制剂) 与R-CHOP化疗在DLBCL的前线设置中结合的安全性和初步疗效.
评估这种组合对患者报告结果的影响,并探索生物相关性.

主要方法:

一个1b期的研究,涉及使用nivolumab的原始化方法,然后在6个周期内进行nivolumab-R-CHOP组合.
招募了33名患者;25名患者的毒性和22名患者的疗效被评估.
分析了患者报告的结果和生物相关性.

主要成果:

估计的18个月总生存率 (OS) 为95.4%,无进展生存率 (PFS) 为72.7%.
与治疗相关的不良事件与历史的R-CHOP数据可比.
患者报告的结果没有表明生活质量下降.

结论:

与R-CHOP结合的前线尼沃卢马布在DLBCL患者中显示出令人鼓舞的安全性和有效性.
耗尽的T细胞免疫类型可以预测进展和免疫毒性,支持原始化方法的有效性.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...